ES2181298T3 - Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos. - Google Patents
Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos.Info
- Publication number
- ES2181298T3 ES2181298T3 ES98955056T ES98955056T ES2181298T3 ES 2181298 T3 ES2181298 T3 ES 2181298T3 ES 98955056 T ES98955056 T ES 98955056T ES 98955056 T ES98955056 T ES 98955056T ES 2181298 T3 ES2181298 T3 ES 2181298T3
- Authority
- ES
- Spain
- Prior art keywords
- thyroxine
- tumors
- hormonal activity
- ketone
- evil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Utilización de un análogo de cetona tiroxina que tiene la fórmula siguiente para la preparación de un medicamento para el tratamiento de un tumor maligno sensible a los compuestos siguientes en un mamífero, presentando dicho análogo de cetona tiroxina una actividad hormonal significativa y siendo un compuesto capaz de inhibir la velocidad inicial del conjunto de la proteína microtubular in vitro: **fórmula** y sus sales farmacéuticamente aceptables, en la que: X = O, S, CH2, carboxi o ausente; Y = O ó S; R1 = metil ó etil; R2, R3, R4 y R5 se seleccionan independientemente de entre el grupo que consta de: H, alquil C1-C4, alquenil C1-C4, alquinil C1-C4, hidroxil, alcoxi C1-C4 y halógeno; R6, R7, R8 y R9 se seleccionan independientemente de entre el grupo que consta de: H, alquil C1-C4, alquenil C1-C4, alquinil C1-C4, hidroxil, alcoxi C1-C4, halógeno, NO2 y NH2; y R10 se selecciona de entre el grupo que consta de alquil C1-C4, alquenil C1-C4 y alquinil C1-C4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/956,711 US5922775A (en) | 1997-10-23 | 1997-10-23 | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2181298T3 true ES2181298T3 (es) | 2003-02-16 |
Family
ID=25498590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98955056T Expired - Lifetime ES2181298T3 (es) | 1997-10-23 | 1998-10-23 | Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5922775A (es) |
| EP (1) | EP1024800B1 (es) |
| AT (1) | ATE222489T1 (es) |
| AU (1) | AU1195499A (es) |
| DE (1) | DE69807349T2 (es) |
| ES (1) | ES2181298T3 (es) |
| WO (1) | WO1999020263A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| KR20010042168A (ko) * | 1998-03-25 | 2001-05-25 | 바이오소스 테크놀로지스 인코포레이티드 | 혈관형성을 저해하는 벤조에이트 유도체 |
| US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
| US6326402B1 (en) * | 1998-08-12 | 2001-12-04 | Octamer, Inc. | Methods for treating viral infections using a compound capable of inhibiting microtubules |
| US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
| EP2428516A1 (en) * | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| EP1906948A4 (en) * | 2005-07-18 | 2010-03-17 | Bipar Sciences Inc | TREATMENT OF CANCER |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| WO2008030887A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| WO2009051815A1 (en) * | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| WO2009064738A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| AU2017355402A1 (en) | 2016-11-02 | 2019-05-30 | Health Research, Inc. | Combination treatment with antibody-drug conjugates and PARP inhibitors |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| SG11201906671SA (en) * | 2017-02-03 | 2019-08-27 | Univ California | Compositions and methods for inhibiting reticulon 4 |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| WO2018237327A1 (en) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| EP3687501A4 (en) | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | INIPARIB FORMULATIONS AND THEIR USES |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| MA53433A (fr) * | 2018-08-24 | 2021-06-30 | Xeniopro GmbH | Éthers phénoxy(hétéro)aryle à activité antiproliférative |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB642159A (en) * | 1947-10-23 | 1950-08-30 | Glaxo Lab Ltd | Improvements in or relating to the preparation of diphenyl ethers |
| GB643089A (en) * | 1947-10-23 | 1950-09-15 | Glaxo Lab Ltd | Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers |
| US4724234A (en) * | 1982-09-17 | 1988-02-09 | Therapeutical Systems Corp. | Method for producing oncolysis |
| US4816255A (en) * | 1985-07-31 | 1989-03-28 | Ghent William R | Treatment of iodine deficiency breast syndrome |
| GB9211415D0 (en) * | 1992-05-29 | 1992-07-15 | Ici Plc | Process for the production of purified terephthalic acid |
| US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
-
1997
- 1997-10-23 US US08/956,711 patent/US5922775A/en not_active Expired - Lifetime
-
1998
- 1998-10-23 EP EP98955056A patent/EP1024800B1/en not_active Expired - Lifetime
- 1998-10-23 AU AU11954/99A patent/AU1195499A/en not_active Abandoned
- 1998-10-23 WO PCT/US1998/022383 patent/WO1999020263A1/en not_active Ceased
- 1998-10-23 DE DE69807349T patent/DE69807349T2/de not_active Expired - Lifetime
- 1998-10-23 ES ES98955056T patent/ES2181298T3/es not_active Expired - Lifetime
- 1998-10-23 AT AT98955056T patent/ATE222489T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| AU1195499A (en) | 1999-05-10 |
| ATE222489T1 (de) | 2002-09-15 |
| EP1024800B1 (en) | 2002-08-21 |
| DE69807349D1 (de) | 2002-09-26 |
| WO1999020263A1 (en) | 1999-04-29 |
| US5922775A (en) | 1999-07-13 |
| DE69807349T2 (de) | 2003-01-02 |
| EP1024800A1 (en) | 2000-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0954299T3 (da) | Thyroxin-analoger uden signifikant hormonal aktivitet til behandling af ondartede tumorer | |
| AU1195499A (en) | Thyroxine analogues having no significant hormonal activity to treat malignant tumors | |
| BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
| BR0112038A (pt) | Triazolopirimidinas substituìdas como agentes anticâncer | |
| ATE461698T1 (de) | Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden | |
| DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
| ATE501722T1 (de) | Therapeutische behandlung androgenrezeptorbedingter leiden | |
| BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| ES2071484T3 (es) | Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral. | |
| ES2151467T1 (es) | Inhibicion de la actividad de la quinasa p38 por aril-ureas. | |
| DE69839586D1 (de) | Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung | |
| MX9701385A (es) | Preparacion de producto combinado para usarse en enfermedades inmunologicas. | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
| ES2154693T3 (es) | Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias. | |
| ES2068705T3 (es) | Tratamiento de la enfermedad neoplastica con interleuquina-10. | |
| DE60233261D1 (de) | Inhibitoren von humanem adam-10 | |
| DE69724682D1 (de) | Verwendung von Gonadotropin releasing Hormon Analogen oder änlichen Verbindungen zur Herstellung von pharmazeutischen Zubereitungen als Zusatz für invasiver Behandlung von Karzinomen | |
| ES2179204T3 (es) | Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales. | |
| NO932101L (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
| NO994330L (no) | Metode for behandling av en tumor | |
| WO2023164455A3 (en) | Compositions and methods to modulate the immune system | |
| BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
| ES2114615T3 (es) | Nueva sonda para el diagnostico de tumores o la terapia de tumores. | |
| PT100111A (pt) | Composicao para o tratamento de um mamifero sofrendo de doenca proliferativa dapele, benigna ou maligna, compreendendo um analogo de somatostatina |